BARBIERI, VITTORIO

BARBIERI, VITTORIO  

Mostra records
Risultati 1 - 16 di 16 (tempo di esecuzione: 0.024 secondi).
Titolo Data di pubblicazione Autore(i) File
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 1-gen-2022 Staropoli, N.; Arbitrio, M.; Salvino, A.; Scionti, F.; Ciliberto, D.; Ingargiola, R.; Labanca, C.; Agapito, G.; Iuliano, E.; Barbieri, V.; Cuce, M.; Zuccala, V.; Cannataro, M.; Tassone, P.; Tagliaferri, P.
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 1-gen-2022 D'Apolito, M.; Spagnuolo, R.; Siciliano, M. A.; Barbieri, V.; Cosco, C.; Fiorillo, L.; Cuomo, O.; Zuccala, V.; Correale, P.; Pensabene, L.; Rossi, M.; Doldo, P.; Tassone, P.; Tagliaferri, P.
Case Report: Identification of a Novel Pathogenic Germline TP53 Variant in a Family With Li–Fraumeni Syndrome 1-gen-2021 Paduano, F.; Fabiani, F.; Colao, E.; Trapasso, F.; Perrotti, N.; Barbieri, V.; Baudi, F.; Iuliano, R.
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 1-gen-2020 Correale, P.; Saladino, R. E.; Giannarelli, D.; Giannicola, R.; Agostino, R.; Staropoli, N.; Strangio, A.; Del Giudice, T.; Nardone, V.; Altomonte, M.; Pastina, P.; Tini, P.; Falzea, A. C.; Imbesi, N.; Arcati, V.; Romeo, G.; Caracciolo, D.; Luce, A.; Caraglia, M.; Giordano, A.; Pirtoli, L.; Necas, A.; Amler, E.; Barbieri, V.; Tassone, P.; Tagliaferri, P.
Distinctive role of the systemic inflammatory profile in non-small-cell lung cancer younger and elderly patients treated with a pd-1 immune checkpoint blockade: A real-world retrospective multi-institutional analysis 1-gen-2021 Nardone, V.; Giannicola, R.; Giannarelli, D.; Saladino, R. E.; Azzarello, D.; Romeo, C.; Bianco, G.; Rizzo, M. R.; Di Meo, I.; Nesci, A.; Pastina, P.; Falzea, A. C.; Caracciolo, D.; Reginelli, A.; Caraglia, M.; Luce, A.; Mutti, L.; Giordano, A.; Cappabianca, S.; Pirtoli, L.; Barbieri, V.; Tassone, P.; Tagliaferri, P.; Correale, P.
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 1-gen-2019 Giannicola, R.; D'Arrigo, G.; Botta, C.; Agostino, R.; Del Medico, P.; Falzea, A. C.; Barbieri, V.; Staropoli, N.; Del Giudice, T.; Pastina, P.; Nardone, V.; Monoriti, M.; Calabrese, G.; Tripepi, G.; Pirtoli, L.; Tassone, P.; Tagliaferri, P.; Correale, P.
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 1-gen-2022 Siciliano, M A; Caridà, G; Ciliberto, D; D'Apolito, M; Pelaia, C; Caracciolo, D; Riillo, C; Correale, P; Galvano, A; Russo, A; Barbieri, V; Tassone, P; Tagliaferri, P
Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer 1-gen-2001 Baudi, F; Quaresima, B; Grandinetti, C; Cuda, G; Faniello, C; Tassone, P; Barbieri, V; Bisegna, R; Ricevuto, E; Conforti, S; Viel, A; Marchetti, P; Ficorella, C; Radice, P; Costanzo, F; Venuta, S.
Exercise therapy as treatment for oncologic disease after a diagnosis of early-stage cancer: effects on lifestyle 1-gen-2015 Iona, T; Ammendolia, A; Inzitari, Mt; Barbieri, V; Tassone, P; Tagliaferri, P; Iocco, M
From single level analysis to multi-omics integrative approaches: A powerful strategy towards the precision oncology 1-gen-2018 Gallo Cantafio, M. E.; Grillone, K.; Caracciolo, D.; Scionti, F.; Arbitrio, M.; Barbieri, V.; Pensabene, L.; Guzzi, P. H.; Di Martino, M. T.
Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives 1-gen-2018 Arbitrio, M; Martino, Mtd; Scionti, F; Barbieri, V; Pensabene, L; Tagliaferri, P
Possibility of identification and expression modality of bronchogenic carcinoma 1-gen-1995 Marsico, S. A.; Barbieri, V.; Pelaia, G.; Calabrese, C.
Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR), Platelet-to-Lymphocyte Ratio (PLR) and Lymphocyte-to-C Reactive Protein Ratio (LCR) in Patients with Hepatocellular Carcinoma (HCC) undergoing Chemoembolizations (TACE) of the Liver: The Unexplored Corner Linking Tumor Microenvironment, Biomarkers and Interventional Radiology 1-gen-2023 Minici, R; Siciliano, Ma; Ammendola, M; Santoro, Rc; Barbieri, V; Ranieri, G; Lagana, D
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 1-gen-2023 Tassone, P.; Di Martino, M. T.; Arbitrio, M.; Fiorillo, L.; Staropoli, N.; Ciliberto, D.; Cordua, A.; Scionti, F.; Bertucci, B.; Salvino, A.; Lopreiato, M.; Thunarf, F.; Cuomo, O.; Zito, M. C.; De Fina, M. R.; Brescia, A.; Gualtieri, S.; Riillo, C.; Manti, F.; Caracciolo, D.; Barbieri, V.; Di Paola, E. D.; Di Francesco, A. E.; Tagliaferri, P.
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 1-gen-2019 Cucè, M; Gallo Cantafio, Me; Siciliano, Ma; Riillo, C; Caracciolo, D; Scionti, F; Staropoli, N; Zuccalà, V; Maltese, L; Di Vito, A; Grillone, K; Barbieri, V; Arbitrio, M; Di Martino, Mt; Rossi, M; Amodio, N; Tagliaferri, P; Tassone, P; Botta, C
Whole gene expression profiling shows a differential transcriptional response to CISPLATINUM in BRCA-1 defective versus BRCA1-reconstituted breast cancer cells 1-gen-2008 Di Martino, Mt; Guzzi, Ph; Ventura, M; Pietragalla, A; Neri, P; Bulotta, A; Calimeri, T; Barbieri, V; Caraglia, M; Veltri, P; Cannataro, M; Tassone, P; Tagliaferri, P